| 中国学者近期发表的论文 |
| 1. | KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer
Author: Xu, Jianming; Ying, Jieer; Liu, Rongrui; Wu, Jun; Ye, Feng; Xu, Nong; Zhang, Yanqiao; Zhao, Rusen; Xiang, Xiaojun; Wang, Jianhong; Lin, Xiaoyan; Xu, Huiting; Gao, Shegan; Luo, Suxia; Guo, Baohong; Li, Xionghui; Su, Yangzhi; Wang, Qian
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 1-12. DOI: 10.1016/j.ejca.2022.10.004 PubMed DOI |
| 2. | Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
Author: Swain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 70-81. DOI: 10.1016/j.ejca.2022.09.024 PubMed DOI |
| 3. | Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
Author: Sheng, Xinan; Ye, DingWei; Zhou, Aiping; Yao, Xin; Luo, Hong; He, Zhisong; Wang, Zengjun; Zhao, Yingchao; Ji, Zhigang; Zou, Qing; He, Chaohong; Guo, Jianming; Tu, Xinhua; Liu, Ziling; Shi, Benkang; Liu, Ben; Chen, Peng; Wei, Qiang; Hu, Zhiquan; Zhang, Yanqiao; Jiang, Kui; Zhou, Fangjian; Wu, Dapeng; Fu, Cheng; Li, Xingya; Wu, Bin; Wang, Lijie; Qin, Shukui; Li, Gang; Liu, Yunpeng; Guo, Hongqian; Chen, Kehe; Zhang, Dahong; Wang, Gongxian; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Guo, Jun
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 205-215. DOI: 10.1016/j.ejca.2022.10.025 PubMed DOI |
| 4. | Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
Author: Guo, Ye; Zhang, Weijie; Ying, Jieer; Zhang, Yanqiao; Pan, Yueyin; Qiu, Wensheng; Fan, Qingxia; Xu, Qi; Ma, Yue; Wang, Gang; Guo, Jing; Su, Weiguo; Fan, Songhua; Tan, Panfeng; Wang, Yan; Luo, Yang; Zhou, Hui; Li, Jin
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 181, Issue , pp. 26-37. DOI: 10.1016/j.ejca.2022.12.004 PubMed DOI |
| 5. | Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
Author: Cueva, Juan F.; Palacio, Isabel; Churruca, Cristina; Herrero, Ana; Pardo, Beatriz; Constenla, Manuel; Santaballa, Ana; Manso, Luis; Estevez, Purificacin; Maximiano, Constanza; Legeren, Marta; Marquina, Gloria; de Juan, Ana; Quindos, Maria; Sanchez, Luisa; Barquin, Arantzazu; Fernandez, Isaura; Martin, Cristina; Juarez, Asuncin; Martin, Teresa; Garcia, Yolanda; Yubero, Alfonso; Gallego, Alejandro; Bueno, Alejandro Martinez; Guerra, Eva; Gonzalez-Martin, Antonio
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 3-14. DOI: 10.1016/j.ejca.2022.12.023 PubMed DOI |
| 6. | Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
Author: Wang, Xuan; Wu, Xiaowen; Yang, Yue; Xu, Weiran; Tian, Hui; Lian, Bin; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Zhou, Li; Mao, Lili; Li, Siming; Tang, Bixia; Yan, Xieqiao; Bai, Xue; Guo, Jun; Cui, ChuanLiang
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 57-65. DOI: 10.1016/j.ejca.2022.12.027 PubMed DOI |
| 7. | First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Author: Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I.; Penrod, John R.; Carbone, David P.
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 183, Issue , pp. 174-187. DOI: 10.1016/j.ejca.2023.01.015 PubMed DOI |
| 8. | OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Author: Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 39-47. DOI: 10.1016/j.ejca.2023.01.031 PubMed DOI |
| 9. | Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2-advanced breast cancer (FRIEND study)
Author: Wang, Jiayu; Cai, Li; Song, Yanqiu; Sun, Tao; Tong, Zhongsheng; Teng, Yuee; Li, Huiping; Ouyang, Quchang; Chen, Qianjun; Cui, Shude; Yin, Yongmei; Liao, Ning; Sun, Qiang; Feng, Jifeng; Wang, Xiaojia; Xu, Binghe
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 73-82. DOI: 10.1016/j.ejca.2023.02.007 PubMed DOI |
| 10. | Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose-response meta-analysis
Author: Yan, Lun-Jie; Yang, Long-Shan; Yan, Yu-Chuan; Tan, Si-Yu; Ding, Zi-Niu; Liu, Hui; Wang, Dong-Xu; Li, Tao
Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 185, Issue , pp. 150-163. DOI: 10.1016/j.ejca.2023.03.005 PubMed DOI |
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
